Cannabis Science Announces Corporate Changes, Appointing Raymond Dabney As President And CEO And Dr. Dorothy Bray As Scientific Advisory Board Chair And Clinical Development Consultant
COLORADO SPRINGS, Colo., Nov. 6, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that some major corporate changes are taking place, allowing the Company to better position itself to face the continuing evolution of the industry and ongoing and incoming projects and initiatives.
Mr. Raymond C. Dabney, co-founder of the Company will become Director, President and CEO, overseeing day-to-day operations. Mr. Dabney previously served as a management consultant for the Company working closely with Dr. Dorothy Bray and the Company's board of directors.
Mr. Dabney is no stranger to great transformation and brings over 25 years of experience in corporate finance, communications, management, sales and marketing. Mr. Dabney has played a lead role in the financing, business development, and public relations programs for several public and private companies. Mr. Dabney's niche market knowledge, team leadership, and management style facilitate growth and forward thinking that successfully brings his projects from concept to completion.
Dr. Bray who is ImmunoClin Corporation's Founder, President and CEO will continue working closely with Cannabis Science. The two companies have recently signed a collaboration agreement in which ImmunoClin Corporation (IMCL) will provide laboratory facilities and services to support a ground breaking joint research project between Cannabis Science and Unistraw Holdings Pce Ltd. of Singapore with operations in India to develop cannabis and cannabinoid-based novel formulations. Dr. Bray will focus on the Company's drug research and development as Clinical Development Consultant and Chair of the Cannabis Science Scientific Advisory Board. She will also be involved in the Michigan cannabis initiative working with Michigan Green Technologies LLC (MGT), a Cannabis Science affiliate, and contribute to several of Cannabis Science's European projects and initiatives, including ongoing development of cannabinoid-based formulation for neurological disorders. "I am delighted to be able to hand over the leadership of Cannabis Science to Mr. Dabney, allowing me to focus on scientific research and the challenge of bringing novel products to market during this rapidly evolving era in the cannabis industry that we are facing today," commented Dr. Bray.
Additionally, going forward, Mr. Dabney will be creating specific drug development teams with Dr. Bray and the Scientific Advisory Board to target particular projects and accelerate the research and development process. These particular teams will be headed by some of the leading experts, including Dr. Roscoe Moore, Special Senior Advisor to the company and retired US Assistant Surgeon General; Mario Lap, Director of European Operations for Cannabis Science, along with other key leaders to be announced with their new positions and responsibilities.
Along with these managerial changes, Cannabis Science has revised its website www.cannabisscience.com to make it more user friendly and provide new proactive information sharing and processes. The new website includes a beta version of the Patient Access Center (PAC). The PAC, is a social network that will allow current and former patients, caregivers, doctors and investors to login, share, and update relevant and pertinent data on medical cannabis, as well as personal experiences, anecdotes, answers to questions, and the like. Visitors will also be able to contact the company directly.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," "intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.